雅创医药技术（上海）有限公司 HEPAGENE
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Hepagene Therapeutics Announces FDA Clearance of Investigational New Drug Application (IND) for HPG7233 THR Beta Agonist 2023-09-20 22:00
Hepagene Therapeutics to Present at the European Association for the Study of the Liver (EASL) Congress 2023 2023-05-25 22:00
Hepagene Therapeutics Reports Positive Top-line Results for Phase 2a RISE Study of FXR Agonist HPG1860 in Patients with NASH 2023-01-19 23:00
Hepagene Therapeutics Initiates the RISE Study, a Phase IIa Clinical Trial of HPG1860 in Patients with NASH 2021-12-02 23:00
Hepagene Therapeutics, Inc. Announces Positive Results from Phase I Trial of HPG1860 2021-08-23 22:00
Hepagene Therapeutics, Inc, Announces Dosing of First Healthy Subject in a Phase I Study of HPG1860 for NASH 2019-10-16 18:00
1